IP Library Granted Patent US 10,179,137
Granted Patent B2
US 10,179,137 · App. 16/054,353 · Granted Jan 15, 2019

Topical formulations comprising a steroid

Inventors: Udhumansha Ubaidulla (Namakkal, IN); Sateesh Kandavilli (Plainsboro, NJ); Ajay Sunil Vairale (Hyderbad, IN); Jeffrey A. Wayne (Markham, CA); Vijendra Nalamothu (Basking Ridge, NJ); Mistry Meghal (Ahmedabad, IN); Refika Isil Pakunlu (Highland Park, NJ)
Assignee: PROMIUS PHARMA LLC
A61K31/573A61K9/0014A61K9/107A61K9/7015A61K31/56A61K31/575A61K31/58A61K47/10A61K47/14A61K47/22A61K47/26A61K47/32A61K47/36A61K47/38A61K47/44B05B1/02B05B1/30B05B11/3045B05B15/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,137
App. No.
16/054,353
Granted
Jan 15, 2019
Kind
B2
Abstract

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Claims (46)

1. A sprayable topical composition comprising:

a) a betamethasone compound;

b) an emulsifying agent;

c) an emollient selected from vegetable oils, fatty acids, fatty acid esters, glycols, and aliphatic alcohols;

d) a water-immiscible substance selected from vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof; and

e) water.

2. The composition according to claim 1 , wherein the betamethasone compound is selected from betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

3. The composition according to claim 1 , wherein the betamethasone compound is in an amount equivalent to from about 0.025 to about 0.1 percent by weight of betamethasone base.

4. The composition according to claim 1 , wherein the emulsifying agent is selected from a cationic surfactant, anionic surfactant, zwitterionic surfactant, amphoteric surfactant, or any combination thereof.

5. The composition according to claim 4 , wherein the emulsifying agent is selected from a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydrides with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, or any combination thereof.

6. The composition according to claim 1 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

7. The composition according to claim 1 , wherein the composition is propellant free.

8. The composition according to claim 1 , wherein the composition is substantially free of propylene glycol.

9. The composition according to claim 1 , wherein the composition is non-foaming.

10. A method of treating a skin condition in a subject comprising topically administering an effective amount of a composition according to claim 1 to the subject; wherein the skin condition is one or more of atopic dermatitis, seborrheic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction.

11. A sprayable topical composition comprising:

a) a betamethasone compound;

b) an oil phase comprising:

(i) an emulsifying agent is selected from sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, poloxamers, polyethylene glycol ethers of stearic acid and mixtures thereof, and

(ii) a water-immiscible substance; and

c) an aqueous phase comprising: water.

12. The composition according to claim 11 , wherein the betamethasone compound is selected from betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

13. The composition according to claim 11 , wherein the betamethasone compound is in an amount equivalent to from about 0.025 to about 0.1 percent by weight of betamethasone base.

14. The composition according to claim 11 , wherein sorbitan fatty acid esters is sorbitan stearate.

15. The composition according to claim 11 , wherein the water-immiscible substance is selected from vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, or any combination thereof.

16. The composition according to claim 11 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

17. The composition according to claim 11 , wherein the composition is propellant free.

18. The composition according to claim 11 , wherein the composition is substantially free of propylene glycol.

19. The composition according to claim 11 , wherein the composition is non-foaming.

20. A method of treating a skin condition in a subject comprising topically administering an effective amount of a composition according to claim 11 to the subject; wherein the skin condition is one or more of atopic dermatitis, seborrheic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction.

21. A propellant-free topical composition, comprising;

a) a betamethasone compound;

b) an emulsifying agent from about 0.25% w/w to about 45% w/w of the composition;

c) a water-immiscible substance; and

d) water;

wherein the composition is delivered onto the skin in the forms of spray; and

wherein the average particle sizes of the dispersed phase droplets are less than about 500 μm.

22. The composition according to claim 21 , wherein the betamethasone compound is selected from betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

23. The composition according to claim 21 , wherein the betamethasone compound is in an amount equivalent to from about 0.025 to about 0.1 percent by weight of betamethasone base.

24. The composition according to claim 21 , wherein the emulsifying agent is selected from a cationic surfactant, anionic surfactant, zwitterionic surfactant, amphoteric surfactant, or any combination thereof.

25. The composition according to claim 24 , wherein the emulsifying agent is selected from a sorbitan fatty acid ester, a mixture of partial esters of sorbitol and its mono- and di-anhydrides with fatty acids, a polyethylene glycol stearate, a glycol stearate, sodium lauryl sulphate, cetyl trialkyl ammonium bromide, a polyoxyethylene sorbitan fatty acid ester, or any combination thereof.

26. The composition according to claim 21 , wherein the composition is dispensed in a device, and the device produces very fine uniform droplets at a specified spray rate from about 20 to about 500 mg/actuation.

27. The composition according to claim 21 , wherein the water-immiscible substance is selected from vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, or any combination thereof.

28. The composition according to claim 21 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

29. The composition according to claim 21 , wherein the composition is propellant free, substantially free of propylene glycol and non-foaming.

30. A method of treating a skin condition in a subject comprising topically administering an effective amount of a composition according to claim 21 to the subject; wherein the skin condition is one or more of atopic dermatitis, seborrheic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reaction.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: ENCORE DERMATOLOGY, INC.
To: PRIMUS PHARMACEUTICALS, INC.
Reel/Frame 055576/0523 →
SECURITY INTEREST Recorded Nov 11, 2020
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: PENNRX VENTURES, LLC
Reel/Frame 054337/0330 →
SECURITY INTEREST Recorded Apr 22, 2019
From: ENCORE DERMATOLOGY, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 048958/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 048941/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2018
From: UBAIDULLA, UDHUMANSHA; KANDAVILLI, SATEESH; VAIRALE, AJAY SUNIL; WAYNE, JEFFREY A.; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; PAKUNLU, REFIKA ISIL
To: DR. REDDY'S LABORATORIES LTD.
Reel/Frame 046551/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2018
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 046551/0305 →
Priority Claims (1)
IN 2111/CHE/2009 · Aug 31, 2009 · national
Continuity (11)
Continuation 15928332 · Mar 22, 2018
Continuation 15843590 · Dec 15, 2017
Continuation 15690851 · Aug 30, 2017
Continuation 15495148 · Apr 24, 2017
Continuation 15226684 · Aug 2, 2016
Continuation 15135259 · Apr 21, 2016
Continuation 15135298 · Apr 21, 2016
Continuation 13391972 · May 7, 2012
Continuation 13391972
Provisional Application 61256554 · Oct 30, 2009
Related Publication 20180338986A1 · Nov 29, 2018